Mitomicina Accord Healthcare (Mitomycin)

Mitomycin is employed in the management of solid tumours where DNA cross‑linking provides therapeutic benefit.

• Bladder cancer: used as intravesical or systemic therapy to reduce tumour recurrence and progression.
• Stomach cancer: administered intravenously as part of combination chemotherapy to improve response rates.
• Pancreatic cancer: incorporated into multi‑drug regimens to enhance cytotoxic effect against pancreatic tumour cells.
• Breast cancer: used in advanced disease settings to achieve tumour shrinkage when combined with other agents.
• Head and neck cancer: given intravenously to potentiate radiotherapy effects and control local disease.

• Mitomycin exerts its antineoplastic activity by undergoing enzymatic reduction within tumor cells to generate reactive intermediates that form covalent bonds between opposite strands of DNA. This cross‑linking prevents DNA strand separation, thereby inhibiting DNA synthesis and transcription, ultimately triggering apoptosis and cell death in rapidly proliferating malignant cells. The drug preferentially accumulates in hypoxic tumor regions, and its cytotoxic effect is enhanced by concurrent radiation therapy.

Mitomycin may cause a spectrum of adverse reactions, ranging from mild gastrointestinal and hematologic effects to rare but potentially life‑threatening organ toxicities.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during treatment.
• Decreased white blood cell count (leukopenia): reduced immunity increasing infection risk.
• Low platelet count (thrombocytopenia): heightened bleeding tendency.
• Fatigue or weakness: general lack of energy affecting daily activities.
• Mouth sores (stomatitis): painful ulcerations in the oral cavity.
• Diarrhea: loose stools that may lead to dehydration.
• Hair loss (alopecia): temporary shedding of scalp hair.
• Elevated liver enzymes (transaminitis): mild hepatic irritation detectable in blood tests.

Serious or Rare Side Effects

• Severe bone marrow suppression (anemia): profound reduction in red blood cells causing fatigue and dyspnea.
• Pulmonary toxicity (interstitial pneumonitis): inflammation of lung tissue leading to cough and shortness of breath.
• Life‑threatening allergic reaction (anaphylaxis): rapid onset of hives, swelling, and airway compromise.
• Renal toxicity (kidney damage): impaired kidney function reflected by rising creatinine.
• Severe skin reaction (Stevens‑Johnson syndrome): extensive blistering and mucosal involvement requiring hospitalization.
• Cardiac toxicity (myocarditis): inflammation of heart muscle that may cause arrhythmias.
• Severe infection due to immunosuppression: opportunistic pathogens causing sepsis.

When using Mitomycin, clinicians should observe several precautionary measures to minimize risks.

• Monitor blood counts: perform regular complete blood count tests to detect leukopenia, thrombocytopenia, and anemia.
• Assess organ function: evaluate hepatic and renal function before each cycle to adjust dosing.
• Avoid concurrent nephrotoxic drugs: limit use of other agents that may worsen kidney injury.
• Use protective anti‑emetics: administer prophylactic anti‑emetic therapy to reduce nausea and vomiting.
• Educate patients on infection signs: instruct patients to report fever, chills, or sore throat promptly.
• Store at ambient temperature: keep the product below 25 °C in the original packaging, protected from moisture and light.

Mitomycin can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

• Concurrent use with other alkylating agents: may cause excessive bone marrow suppression.
• Combination with high‑dose radiation therapy: increases risk of severe tissue damage.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (e.g., fluconazole): can inhibit metabolism and raise Mitomycin plasma levels.
• Nephrotoxic antibiotics (e.g., aminoglycosides): may enhance renal toxicity.
• Drugs affecting hepatic enzymes (e.g., CYP inducers): may alter drug clearance.